Filed with ASX · · 4 pages · English
Clarity Pharmaceuticals Ltd. has announced that it has achieved its recruitment target for the Cohort Expansion Main Group of the SECuRE trial, which focuses on treating metastatic castration-resistant prostate cancer. The trial has enrolled participants to evaluate the efficacy and safety of a specific radiopharmaceutical treatment, with ongoing recruitment for additional participants. The company reports promising results regarding the treatment's safety profile and efficacy, with a significant percentage of participants achieving disease control. Clarity's Executive Chairperson highlighted the milestone as a significant step towards advancing their theranostic product for prostate cancer treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/secure-update-1
E: investor@claritypharmaceuticals.com W: www.claritypharmaceuticals.com ACN: 143 005 341 T: +61 (0)2 9209 4037 CLARITY PHARMACEUTICALS LIMITED 1 1 E: investor@claritypharmaceuticals.com W: www.claritypharmaceuticals.com ACN: 143 005 341 T: +61 (0)2 9209 4037 CLARITY PHARMACEUTICALS LIMITED...
Clarity Pharmaceuticals Ltd. on 6ix
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals